. Enfin, Il aurait été intéressant de comparer les données du Fibroscan des différents patients en fonction de ce paramètre afin de déterminer si le degré de fibrose augmente avec la durée d

J. Ludwig, T. Viggiano, D. B. Mcgill, and B. J. Ott, Nonalcoholic steatohepatitis : Mayo Clinic experiences with a hitherto unnamed disease Mayo Clin Proc, vol.55, pp.434-442, 1980.

V. Ratziu, A position statement on NAFLD/NASH based on the EASL 2009 special conference, J Hepatol, vol.53, issue.2, pp.372-84, 2010.

Z. M. Younossi, A. B. Koenig, D. Abdelatif, Y. Fazel, L. Henry et al., Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, vol.64, issue.1, pp.73-84, 2016.

J. D. Browning, L. S. Szczepaniak, and R. Dobbins, Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity, Hepatology, vol.40, issue.6, pp.1387-95, 2004.

C. D. Williams, J. Stengel, and M. I. Asike, Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study, Gastroenterology, vol.140, issue.1, pp.124-155, 2011.

C. Estes, H. Razavi, R. Loomba, Z. Younossi, and A. J. Sanyal, Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease, Hepatology, vol.67, issue.1, pp.123-133, 2018.

Z. M. Younossi, M. Stepanova, and M. Afendy, Changes in the prevalence of the most common causes of chronic liver diseases in the United States from, Clin Gastroenterol Hepatol, vol.9, issue.6, pp.524-530, 1988.

J. Frith, C. P. Day, E. Henderson, A. D. Burt, and J. L. Newton, Non-alcoholic fatty liver disease in older people, Gerontology, vol.55, issue.6, pp.607-620, 2009.

A. E. Reid, Nonalcoholic steatohepatitis, Gastroenterology, vol.121, issue.3, pp.710-733, 2001.

G. Marchesini, M. Brizi, and A. M. Marsell-labate, Association of non alcoholic fatty liver disease with insulin resistance, Am J Med, vol.107, issue.5, pp.450-455, 1999.

Y. E. Chon, K. J. Kim, and K. S. Jung, The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter, Yonsei Med J, vol.57, issue.4, pp.885-92, 2016.

P. Angulo, J. C. Keach, K. P. Batts, and K. D. Lindor, Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis, Hepatology, vol.30, issue.6, pp.1356-62, 1999.

R. Kwok, K. C. Choi, and G. L. Wong, Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study, Gut, vol.65, issue.8, pp.1359-68, 2016.

B. W. Smith and L. A. Adams, Nonalcoholic fatty liver disease and diabetes mellitus: Pathogenesis and treatment, Nat Rev Endocrinol, vol.7, issue.8, pp.456-65, 2011.

Z. M. Younossi, P. Golabi, and L. Avila, The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis, J Hepatol, 2019.

S. Ballestri, S. Zona, and G. Targher, Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis, J Gastroenterol Hepatol, vol.31, issue.5, pp.936-980, 2016.

J. B. Dixon, P. S. Bhathal, O. 'brien, and P. E. , Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese, Gastroenterology, 2001.

B. Balkau, M. Vernay, and L. Mhamdi, The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome, The French D.E.S.I.R. study. Diabetes Metab, vol.29, pp.526-558, 2003.

. Ncd-risc, Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants, Lancet, vol.387, pp.1377-1396, 2016.

. Obépi, Enquête épidémiologique nationale sur le surpoids et l'obésité, 2012.

J. G. Fan and H. X. Cao, Role of diet and nutritional management in non-alcoholic fatty liver disease, J Gastroenterol Hepatol, vol.28, issue.4, pp.81-88, 2013.

G. E. Chung, D. Kim, and W. Kim, Non-alcoholic fatty liver disease across the spectrum of hypothyroidism, J. Hepatol, vol.57, issue.1, pp.150-156, 2012.

A. Eshraghian, H. Jahromi, and A. , Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review, World J Gastroenterol, vol.20, issue.25, pp.8102-8109, 2014.

A. Mantovani, F. Nascimbeni, and A. Lonardo, Association between primary hypothyroidism and nonalcoholic fatty liver disease: a systematic review and meta-analysis, Thyroid, vol.28, issue.10, pp.1270-84, 2018.

D. N. Amarapurka, A. D. Amarapurkar, and N. D. Patel, Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis, Ann Hepatol, vol.5, issue.1, pp.30-33, 2006.

P. Mofrad, M. J. Contos, and M. Haque, Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values, Hepatology, vol.37, issue.6, pp.1286-92, 2003.

S. Verma, D. Jensen, J. Hart, and S. R. Mohanty, Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)

, Liver Int, issue.9, pp.1398-405, 2013.

G. Targher, L. Bertolini, and S. Rodella, Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care, vol.30, pp.2119-2140, 2007.

E. , Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease, J Hepatol, vol.64, issue.6, pp.1388-402, 2016.

V. Ratziu, C. F. Heurtier, and A. , Sampling variability of liver biopsy in nonalcoholic fatty liver disease, Gastroenterology, vol.128, issue.7, pp.1898-906, 2005.

J. F. Cadranel, P. Rufat, and F. Degos, Practices of Liver Biopsy in France : Results of a Prospective Nationwide Survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF), Hepatology, vol.32, issue.3, pp.477-81, 2000.

A. A. Bravo, S. G. Sheth, and S. Chopra, Liver biopsy, N Engl J Med, vol.344, issue.7, pp.495-500, 2001.

G. Xiao, S. Zhu, X. X. Yan, L. Yang, J. Wu et al., Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis, Hepatology, vol.66, issue.5, pp.1486-1501, 2017.

P. Angulo, J. M. Hui, and G. Marchesini, The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology, vol.45, pp.846-854, 2007.

L. Castera, J. Vergniol, and J. Foucher, Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C

, Gastroenterology, vol.128, issue.2, pp.343-50, 2005.

V. Ratziu, J. Massard, and F. Charlotte, Diagnostic value of biochemical markers (Fibrotest®-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease, BMC Gastroenterol, vol.6, p.6, 2006.

A. L. Tropet, F. Laine, and V. De-ledinghen, Non invasive tests of liver fibrosis in NAFLD, J Hepatol, vol.46, pp.287-288, 2007.

J. Boursier, V. De-ledinghen, and V. Leroy, A stepwise algorithm using an at-a-glance firstline test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis, J Hepatol, vol.6, issue.66, pp.1158-65, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02448903

A. E. Joseph, S. H. Saverymuttu, A. , S. Cook, M. G. Maxwell et al., Comparison of liver histology with US in assessing diffuse parenchymal liver disease, Clin Radiol, 1991.

L. Huwart, C. Sempoux, and E. Vicaut, Magnetic resonance elastography for the noninvasive staging of liver fibrosis, Gastroenterology, vol.135, issue.1, pp.32-40, 2008.

P. Angulo, D. E. Kleiner, and S. Dam-larsen, Liver fibrosis, but no other histologic features, associates with long-term outcomes of patients with nonalcoholic fatty liver disease

, Gastroenterology, vol.149, issue.2, pp.389-97, 2015.

G. Targher, L. Bertolini, and R. Padovani, Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care, 2007.

B. Condat, A. J. Remy, and V. Jouannaud, Groupe d'étude de l'ANGH. Le recours aux soins pour cirrhose dans les services d'hépato-gastroentérologie des centres hospitaliers généraux français, Bull Epidémiol Hebd, pp.450-456, 2012.

B. Liu, A. Balkwill, G. Reeves, and V. Beral, Million Women Study Collaborators. Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study, BMJ, vol.340, p.912, 2010.

M. Ekstedt, H. Hagstrom, and P. Nasr, Fibrosis stage is the strongest predictor for diseasespecific mortality in NAFLD after up to 33 years of follow-up, Hepatology, vol.61, issue.5, pp.1547-54, 2015.

S. Singh, A. M. Allen, Z. Wang, L. J. Prokop, M. H. Murad et al., Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies, Clin Gastroenterol Hepatol, vol.13, issue.4, pp.643-54, 2015.

S. Shili-masmoudi, G. L. Wong, and J. B. Hiriart, Liver stiffness measurement predicts longterm survival and complications in non-alcoholic fatty liver disease, Liver Int, 2019.

Z. M. Younossi, M. Otgonsuren, and L. Henry, Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from, Hepatology, vol.62, issue.6, pp.1723-1753, 2004.

J. Dyson, B. Jaques, and D. Chattopadyhay, Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team, J Hepatol, vol.60, issue.1, pp.110-117, 2014.

R. Pais, L. Fartoux, and C. Goumard, Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period, Aliment Pharmacol Ther, vol.46, issue.9, pp.856-63, 2017.

J. Polesel, A. Zucchetto, and M. Montella, The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma, Ann Oncol, vol.20, issue.2, pp.353-360, 2009.

S. C. Larsson and A. Wolk, Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies, Br J Cancer, vol.97, issue.7, pp.1005-1013, 2007.

V. Ratziu, L. Bonyhay, D. Martino, and V. , Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis, Hepatology, vol.35, issue.6, pp.1485-93, 2002.

H. B. El-serag, T. Tran, and J. E. Everhart, Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma, Gastroenterology, vol.126, issue.2, pp.460-468, 2004.

J. Ertle, A. Dechene, and J. P. Sowa, Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis, Int J Cancer, vol.128, issue.10, pp.2436-2479, 2011.

M. Ekstedt, L. E. Franzen, and U. L. Mathiesen, Long-term follow-up of patients with NAFLD and elevated liver enzymes, Hepatology, vol.44, issue.4, pp.865-73, 2006.

N. Rafiq, C. Bai, and Y. Fang, Long-term follow-up of patients with nonalcoholic fatty liver

, Clin Gastroenterol Hepatol, vol.7, issue.2, pp.234-242, 2009.

M. R. Charlton, J. M. Burns, R. A. Pedersen, K. D. Watt, J. K. Heimbach et al.,

, Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States, Gastroenterology, vol.141, issue.4, pp.1249-53, 2011.

Z. Younossi, M. Stepanova, and J. P. Ong, Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates, Clinical Gastroenterology and Hepatology, vol.17, issue.4, pp.748-55, 2019.

R. J. Wong, M. Guilar, and R. Cheung, Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States

, Gastroenterology, vol.148, issue.3, pp.547-55, 2015.

C. Bhati, M. O. Idowu, and A. J. Sanyal, Long-term Outcomes in Patients Undergoing Liver Transplantation for Nonalcoholic Steatohepatitis-Related Cirrhosis, Transplantation, 2017.

G. Musso, R. Gambino, D. Michieli, and F. , Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis, Hepatology, 2003.

K. Toshimitsu, B. Matsuura, and I. Ohkubo, Dietary habits and nutrient intake in nonalcoholic steatohepatitis, Nutrition, vol.23, issue.1, pp.46-52, 2007.

M. D. Kontogianni, N. Tileli, and A. Margariti, Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease, Clin Nutr, vol.33, issue.4, pp.678-83, 2014.

E. Vilar-gomez, Y. Martinez-perez, and L. Calzadilla-bertot, Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

, Gastroenterology, vol.149, issue.2, pp.367-378, 2015.

K. Promrat, D. E. Kleiner, and H. M. Niemeier, Randomized controlled trial testing the effects of weight loss on non-alcoholic steatohepatitis, Hepatology, vol.51, issue.1, pp.121-130, 2010.

K. Promrat, D. E. Kleiner, and H. M. Niemeier, Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis, Hepatology, vol.51, issue.1, pp.121-129, 2010.

S. S. Bassuk and J. E. Manson, Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease, J Appl Physiol, 1985.

S. S. Bassuk and J. E. Manson, Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease, J Appl Physiol, 1985.

A. E. Bauman, Updating the evidence that physical activity is good for health: an epidemiological review 2000-2003, J Sci Med Sport, vol.7, issue.1, pp.6-19, 2004.

J. W. Molloy, . Calcagno, . Cj, C. D. Williams, F. J. Jones et al., Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis, Hepatology, vol.55, issue.2, pp.429-436, 2012.

A. Birerdinc, M. Stepanova, L. Pawloski, and Z. M. Younossi, Caffeine is protective in patients with non-alcoholic fatty liver disease, Aliment Pharmacol Ther, vol.35, issue.1, pp.76-82, 2012.

A. A. Modi, J. J. Feld, and Y. Park, Increased caffeine consumption is associated with reduced hepatic fibrosis, Hepatology, vol.51, issue.1, pp.201-210, 2010.

G. Marchesini, M. Brizi, G. Bianchi, S. Tomassetti, M. Zoli et al., Metformin in nonalcoholic steatohepatitis, Lancet, vol.358, issue.9285, pp.893-897, 2001.

A. Duseja, A. Das, and R. K. Dhiman, Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions, Ann Hepatol, vol.6, issue.4, pp.222-228, 2007.

Y. Li, L. Liu, B. Wang, J. Wang, and D. Chen, Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Biomed Rep, vol.1, pp.57-64, 2013.

V. Ratziu, P. Giral, and S. Jacqueminet, Rosiglitazone for nonalcoholic steatohepatitis: oneyear results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) trial, Gastroenterology, vol.135, issue.1, pp.100-110, 2008.

R. Belfort, S. A. Harrison, and K. Brown, A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis, N Engl J Med, vol.355, issue.22, pp.2297-307, 2006.

G. P. Aithal, J. A. Thomas, and P. V. Kaye, Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis, Gastroenterology, 2008.

K. Cusi, B. Orsak, and F. Bril, Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial, Ann Intern Med, vol.165, issue.6, pp.305-320, 2016.

A. J. Sanyal, N. Chalasani, . Kowdley, and . Kv, Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis, N Engl J Med, vol.362, issue.18, pp.1675-85, 2010.

M. Schurks, R. J. Glynn, P. M. Rist, C. Tzourio, and T. Kurth, Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials, BMJ, vol.341, p.5702, 2010.

E. A. Klein, I. M. Thompson, and C. M. Tangen, Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT), JAMA, vol.306, issue.14, 2011.

V. Ratziu, S. A. Harrison, and S. Francque, Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and-delta, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening, Gastroenterology, vol.150, issue.5, pp.1147-1159, 2016.

V. Ratziu, Novel Pharmacotherapy Options for NASH, Dig Dis Sci, vol.61, issue.5, pp.1398-405, 2016.

G. Lassailly, R. Caiazzo, and D. Buob, Bariatric surgery reduces features of non-alcoholic steatohepatitis in morbidly obese patients, Gastroenterology, vol.149, issue.2, pp.377-88, 2015.

R. A. Weiner, Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease, Dig Dis, vol.28, issue.1, pp.274-283, 2010.

H. Garg, S. Aggarwal, and . Shalimar, Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients

, Surg Obes Relat Dis, vol.14, issue.1, pp.81-91, 2018.

S. G. Mattar, L. M. Velcu, and M. Rabinovitz, Surgically-Induced Weight Loss Significantly Improves Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome, Ann Surg, 2005.

V. De-ledinghen, J. Vergniol, J. Foucher, F. El-hajbi, W. Merrouche et al., Feasibility of liver transient elastography with FibroScan® using a new probe for obese patients, Liver Int, vol.30, issue.7, pp.1043-1051, 2010.

M. Friedrich-rust, H. Hadji-hosseini, and S. Kriener, Transient elastography with a new probe for obese patients for non-invasive staging of non-alcoholic steatohepatitis, Eur Radiol, vol.20, issue.10, pp.2390-2396, 2010.

I. Sporea, A. Jurchi?, R. ?irli, S. Bota, and M. Sendroiu, Can transient elastography be a reliable method for assessing liver fibrosis in non alcoholic steatohepatitis (NASH)? Med Ultrason, vol.15, pp.106-116, 2013.

U. Umut-emre-aykut, A. Akyuz, and . Yesil, A comparison of FibroMeter? NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease

, Scandinavian Journal of Gastroenterology, vol.49, issue.11, pp.1343-1391, 2014.

J. Boursier, A. Konate, and M. Guilluy, Learning curve and interobserver reproducibility evaluation of liver stiffness measurement by transient elastography, Eur J Gastroenterol Hepatol, vol.20, issue.7, pp.693-701, 2008.

P. Pathik, S. Ravindra, A. C. Prasad, B. Jatin, P. Prabha et al., Fibroscan versus simple noninvasive screening tools in predicting fibrosis in high-risk nonalcoholic fatty liver disease patients from Western India, Ann Gastroenterol, vol.28, issue.2, pp.281-286, 2015.

Z. M. Younossi, D. Blissett, and R. Bilissett, The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe, Hepatology, 2016.

G. Marchesini, E. Bugianesi, and G. Forlani, Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome, Hepatology, vol.37, issue.4, pp.917-940, 2003.

L. Spahr and N. Goossens, La stéatopathie non alcoolique, Rev Med Suisse, vol.13, pp.215-216, 2017.

F. Bessone, M. V. Razori, and M. G. Roma, Molecular pathways of nonalcoholic fatty liver disease development and progression, Cellular and Molecular Life Sciences, vol.76, pp.99-128, 2018.

, Spectre des lésions hépatiques (98), vol.1

, Annexe n°2 : Epidémiologie de la NAFLD dans le monde

, Annexe n°4 : Evolution des étiologies responsables d'inscription sur la liste de transplantation hépatique (60)

, Au moment d'être admis(e) à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, J'informerai les patients des décisions envisagées, de leurs raisons et de leurs

, Reçu(e) à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément

, Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses ; que je sois déshonoré(e) et méprisé(e) si j'y manque